ANI Pharmaceuticals Inc (ANIP)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 67.56% | 51.76% | 53.07% | 56.94% | 59.59% | 63.41% | 62.83% | 60.35% | 56.13% | 51.83% | 49.12% | 49.18% | 53.45% | 57.05% | 59.25% | 59.98% | 58.19% | 59.63% | 61.88% | 65.48% |
| Operating profit margin | -0.70% | 1.58% | 8.77% | 10.46% | 10.06% | 10.06% | 6.56% | 0.94% | -8.13% | -19.22% | -22.70% | -27.44% | -18.41% | -7.41% | -4.39% | -2.41% | -7.68% | -10.55% | -8.35% | 2.02% |
| Pretax margin | -3.62% | -1.35% | 6.59% | 8.32% | 4.08% | 2.94% | -2.62% | -9.65% | -19.81% | -31.01% | -32.91% | -36.28% | -25.94% | -12.98% | -9.56% | -7.51% | -12.45% | -15.68% | -13.84% | -3.75% |
| Net profit margin | -3.01% | -1.28% | 5.01% | 6.87% | 3.86% | 2.98% | -1.29% | -7.34% | -15.14% | -23.95% | -25.32% | -27.78% | -19.71% | -10.41% | -8.08% | -7.25% | -10.82% | -11.93% | -10.30% | -0.76% |
ANI Pharmaceuticals Inc has shown fluctuations in its profitability ratios over the past few years.
The gross profit margin has been decreasing from 65.48% in March 2020 to 67.56% in December 2024. This indicates a decline in the percentage of revenue retained after deducting the cost of goods sold.
The operating profit margin was negative for several quarters up to December 2022, but improved thereafter, reaching 8.77% in June 2024. This suggests that the company has been able to control its operating expenses better, leading to higher profitability from its core operations.
The pretax margin also demonstrates a similar trend, improving from negative figures in early 2020 to -3.62% in December 2024. This indicates the company's ability to generate profits before accounting for taxes, reflecting better operational efficiency in recent periods.
The net profit margin has also shown improvement, from negative percentages in early 2020 to -3.01% in December 2024. This highlights that after accounting for all expenses, including taxes, ANI Pharmaceuticals Inc has been able to enhance its bottom-line profitability.
Overall, despite the fluctuations, ANI Pharmaceuticals Inc has demonstrated an improvement in its profitability ratios over the years, indicating better cost management and operational efficiency.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -0.34% | 0.68% | 5.13% | 5.92% | 5.41% | 5.08% | 3.06% | 0.44% | -3.38% | -7.36% | -7.59% | -8.33% | -5.16% | -3.35% | -1.95% | -1.11% | -3.47% | -4.54% | -3.54% | 0.85% |
| Return on assets (ROA) | -1.44% | -0.55% | 2.93% | 3.89% | 2.08% | 1.50% | -0.60% | -3.44% | -6.30% | -9.17% | -8.47% | -8.43% | -5.52% | -4.70% | -3.59% | -3.33% | -4.89% | -5.14% | -4.37% | -0.32% |
| Return on total capital | -2.99% | 0.84% | 10.38% | 11.43% | 10.75% | 9.41% | 6.29% | 0.99% | -7.40% | -15.81% | -16.89% | -15.48% | -9.06% | -4.55% | -0.78% | -2.80% | -8.21% | -10.96% | -8.71% | 2.04% |
| Return on equity (ROE) | -4.32% | -1.65% | 5.93% | 7.87% | 4.34% | 2.94% | -1.19% | -7.76% | -14.15% | -20.13% | -18.89% | -18.15% | -11.88% | -11.55% | -8.98% | -7.59% | -11.53% | -12.18% | -10.64% | -0.76% |
ANI Pharmaceuticals Inc's profitability ratios show a fluctuating trend over the period analyzed. The Operating return on assets (Operating ROA) varied between negative figures, reaching a low of -8.33% in March 31, 2022, and gradually improving to 5.13% by June 30, 2024. This indicates that the company's operating income generated from its assets improved over time.
The Return on assets (ROA) also started in negative territory but showed a more volatile pattern throughout the period. It reached its lowest point at -8.47% on June 30, 2022, before increasing to 2.93% by June 30, 2024. This metric suggests that ANI Pharmaceuticals Inc's overall profitability in relation to its assets was erratic but showed some recovery.
Return on total capital had a similar trajectory, with negative values in the earlier periods but improving gradually over time. It rose from -16.89% on June 30, 2022, to 10.38% by June 30, 2024, indicating that the company's profitability concerning its total capital strengthened significantly.
Return on equity (ROE) followed a comparable trend, with negative values initially and then showing improvement as time progressed. From a low of -20.13% on September 30, 2022, the ROE increased to 5.93% by June 30, 2024. This implies that the company's profitability in relation to shareholder equity gained momentum over the period analyzed.
Overall, the profitability ratios of ANI Pharmaceuticals Inc depict a journey from struggling performance to a recovery and improvement in profitability metrics from 2022 to 2024, signaling a positive trend in the company's financial performance.